AU Patent

AU2010200761B2 — Parenteral formulations containing a rapamycin hydroxyester

Assigned to Wyeth LLC · Expires 2011-10-13 · 15y expired

What this patent protects

This invention provides parenteral formulations of rapamycin 42-ester with 3-hydroxy 2(hydroxymethyl)-2-methyl-propionic acid (CCI-779). An embodiment of the invention is a 5 CCI-779 cosolvent concentrate which comprises CCI-779, a parenterally acceptable solvent, and an antioxid…

USPTO Abstract

This invention provides parenteral formulations of rapamycin 42-ester with 3-hydroxy 2(hydroxymethyl)-2-methyl-propionic acid (CCI-779). An embodiment of the invention is a 5 CCI-779 cosolvent concentrate which comprises CCI-779, a parenterally acceptable solvent, and an antioxidant component.

Drugs covered by this patent

Patent Metadata

Patent number
AU2010200761B2
Jurisdiction
AU
Classification
—
Expires
2011-10-13
Drug substance claim
No
Drug product claim
No
Assignee
Wyeth LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.